Aerovate Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Jade Biosciences, a clinical-stage biopharmaceutical company, reported significant pipeline progress for its autoimmune disease therapies and a strong cash position following recent capital raises, despite ongoing net losses.
Aerovate Therapeutics discontinues AV-101 development for PAH following Phase 2b results and enters a merger agreement with Jade Biosciences to maximize shareholder value.
Aerovate Therapeutics, a clinical-stage biopharmaceutical company, has released its full year 2023 results, highlighting progress in its Phase 2b/Phase 3 clinical trial for AV-101, a treatment for pulmonary arterial hypertension.